Tolcher AW, Kurzrock R, Valero V, Gonzalez R, et al. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination
with the oral MEK1/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol 2020;85:673-683.
PMID: 32062691